JHJessica Hartmann

Jessica Hartmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jessica Hartmann has a total of 125 co-authors. Here are the top co-authors by number of shared publications:

  • Christian J. Buchholz

    Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany

    8 shared publications
  • Arezoo Jamali

    Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany

    3 shared publications
  • Irene C. Schneider

    Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, 63225 Langen, Germany

    3 shared publications
  • Julia Herrmann

    From the NK Cell Biology, Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, D-60596 Frankfurt am Main, Germany and

    3 shared publications
  • Laura Kapitza

    Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany

    3 shared publications
  • Steffen Beyer

    The Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am Main, Germany

    3 shared publications

Latest Publications

  • Author Correction: The evolving role of cytokines for CAR-T cell manufacturing and beyond

    by Mar Guaza-Lasheras, Johanna Nimmerfroh, Dominic Schwarz, Tanja D. de Gruijl, Jessica Hartmann, Christian Klein, Heinz Läubli, Michal Lotem, Joerg Mittelstaet, Christophe Paget, et al.

  • Open Access

    The evolving role of cytokines for CAR-T cell manufacturing and beyond

    by Mar Guaza-Lasheras, Johanna Nimmerfroh, Dominic Schwarz, Tanja D. de Grujil, Jessica Hartmann, Christian Klein, Heinz Läubli, Michal Lotem, Joerg Mittelstaet, Christophe Paget, et al.

    Chimeric antigen receptor (CAR)-T cells represent a recent clinically validated modality in cancer therapy and beyond. However, broad industrial implementation faces technological, logistical, regulatory and financial challenges. A major bottleneck is the ex vivo production process, where cytokines are essential and product-determining constituents. To better understand the complexity of cytokine utilization throughout the production process, we rigorously reviewed the existing literature, including extended manufacturing parameters from 292 available clinical reports. We found a progressive reduction of interleukin-2 exposure, driven by its association with unfavourable cell characteristics. Preclinically, this catalysed the evaluation of alternative cytokines with potential to preserve naive phenotypes, support cell expansion and enhance the efficacy of CAR-T cells. Here we illustrate the evolving use of cytokines, reveal non-standardized clinical CAR-T cell manufacturing parameters, and summarize preclinical and next-generation concepts, which may improve manufacturing efficiency, cost-effectiveness and therapeutic outcomes. Our observations may further guide the development of cytokine-armouring strategies to promote in-patient expansion and persistence, even as innovations such as shortened manufacturing and in vivo engineering techniques could reduce reliance on cytokines during ex vivo culture.


  • Open Access

    CAR T-cell-associated secondary malignancies challenge current pharmacovigilance concepts

    by Philipp Berg, Gabriele Ruppert-Seipp, Susanne Müller, Gabriele D Maurer, Jessica Hartmann, Udo Holtick, Christian J Buchholz, Markus B Funk

    Suspected adverse reactions following chimeric antigen receptor T-cell (CAR T) treatment include more and more cases of secondary T-cell malignancies. The causality assessment of such suspected reactions challenges established evaluation practices due to (i) patient and product-specific risk factors and (ii) incomplete data available with post-marketing reports submitted to competent authorities. This is of particular relevance for gene therapy products that integrate into the host genome. We present a summary of case reports related to different CAR T products and the rationale for case causality assessment. In this context, possible pathophysiologic mechanisms and differences between CAR T products to be taken into account are discussed. The unparalleled complexity of the case follow-up and the multistep process of cancer development necessitates a case-by-case consideration. This highlights challenges in the pharmacovigilance of advanced therapy medicinal products and underlines the importance of testing for vector presence, integration location and gene expression profile for an informed case assessment of suspected secondary malignancies with the aim to obtain a better understanding of contributing factors.


  • Open Access

    CD62L as target receptor for specific gene delivery into less differentiated human T lymphocytes

    by Laura Kapitza, Naphang Ho, Thomas Kerzel, Annika M. Frank, Frederic B. Thalheimer, Arezoo Jamali, Thomas Schaser, Christian J. Buchholz, Jessica Hartmann

    Chimeric antigen receptor (CAR)-expressing T cells are a complex and heterogeneous gene therapy product with variable phenotype compositions. A higher proportion of less differentiated CAR T cells is usually associated with improved antitumoral function and persistence. We describe in this study a novel receptor-targeted lentiviral vector (LV) named 62L-LV that preferentially transduces less differentiated T cells marked by the L-selectin receptor CD62L, with transduction rates of up to 70% of CD4+ and 50% of CD8+ primary T cells. Remarkably, higher amounts of less differentiated T cells are transduced and preserved upon long-term cultivation using 62L-LV compared to VSV-LV. Interestingly, shed CD62L neither altered the binding of 62L-LV particles to T cells nor impacted their transduction. The incubation of 2 days of activated T lymphocytes with 62L-LV or VSV-LV for only 24 hours was sufficient to generate CAR T cells that controlled tumor growth in a leukemia tumor mouse model. The data proved that potent CAR T cells can be generated by short-term ex vivo exposure of primary cells to LVs. As a first vector type that preferentially transduces less differentiated T lymphocytes, 62L-LV has the potential to circumvent cumbersome selections of T cell subtypes and offers substantial shortening of the CAR T cell manufacturing process.


  • Open Access

    FcγRIIA-specific DARPins as novel tools in blood cell analysis and platelet aggregation

    by Vanessa Riechert, Sascha Hein, Mayken Visser, Mathias Zimmermann, Jan Wesche, Philipp A. Adams, Samuel A. Theuerkauf, Arezoo Jamali, Andrea Wangorsch, Andreas Reuter, et al.


  • Open Access

    CD62L as target receptor for specific gene delivery into less differentiated human T lymphocytes

    by Laura Kapitza, Naphang Ho, Thomas Kerzel, Annika Frank M, Frederic Thalheimer B, Thomas Schaser, Christian Buchholz, Jessica Hartmann

    Chimeric antigen receptor (CAR) expressing T cells are a complex and heterogeneous gene therapy product with variable phenotype composition. A higher proportion of less differentiated CAR T cells is usually associated with improved antitumoral function and persistence. We describe here a novel receptor-targeted lentiviral vector (LV), named 62L-LV, that preferentially transduces less differentiated T cells marked by the L-selectin receptor CD62L, with transduction rates of up to 70% of CD4 + and 50% of CD8 + primary T cells. Remarkably, higher amounts of less differentiated T cells are transduced and preserved upon long-term cultivation using 62L-LV compared to VSV-LV. Interestingly, shed CD62L neither altered binding of 62L-LV particles to T cells nor impacted their transduction. Incubation of two days activated T lymphocytes with 62L-LV or VSV-LV for only 24 hours was sufficient to generate CAR T cells that controlled tumor growth in an NSG mouse model. The data prove that potent CAR T cells can be generated by short-term ex vivo exposure of primary cells to LVs. As a first vector type that preferentially transduces less differentiated T lymphocytes, 62L-LV has the potential to circumvent cumbersome selection of T cell subtypes and offers substantial shortening of the CAR T cell manufacturing process.


  • Open Access

    Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8

    by Alexander Michels, Annika M. Frank, Dorothee M. Günther, Mehryad Mataei, Kathleen Börner, Dirk Grimm, Jessica Hartmann, Christian J. Buchholz


  • Genetic in vivo engineering of human T lymphocytes in mouse models

    by Tatjana Weidner, Shiwani Agarwal, Séverine Perian, Floriane Fusil, Gundula Braun, Jessica Hartmann, Els Verhoeyen, Christian J. Buchholz

    Receptor targeting of vector particles is a key technology to enable cell type–specific in vivo gene delivery. For example, T cells in humanized mouse models can be modified by lentiviral vectors (LVs) targeted to human T-cell markers to enable them to express chimeric antigen receptors (CARs). Here, we provide detailed protocols for the generation of CD4- and CD8-targeted LVs (which takes ~9 d in total). We also describe how to humanize immunodeficient mice with hematopoietic stem cells (which takes 12–16 weeks) and precondition (over 5 d) and administer the vector stocks. Conversion of the targeted cell type is monitored by PCR and flow cytometry of blood samples. A few weeks after administration, ~10% of the targeted T-cell subtype can be expected to have converted to CAR T cells. By closely following the protocol, sufficient vector stock for the genetic manipulation of 10–15 humanized mice is obtained. We also discuss how the protocol can be easily adapted to use LVs targeted to other types of receptors and/or for delivery of other genes of interest.


  • Open Access

    Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany

    by Nawid Albinger, Jessica Hartmann, Evelyn Ullrich

    Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. Currently, more than 500 CAR-T and 17 CAR-NK cell trials are being conducted worldwide including the four CAR-T cell products Kymriah, Yescarta, Tecartus and Breyanzi, which are already available on the market. Most CAR-T cell-based gene therapy products that are under clinical evaluation consist of autologous enriched T cells, whereas CAR-NK cell-based approaches can be generated from allogeneic donors. Besides modification based on a second-generation CAR, more advanced CAR-immune cell therapeutics are being tested, which utilize precise insertion of genes to circumvent graft-versus-host disease (GvHD) or employ a dual targeting approach and adapter CARs in order to avoid therapy resistance caused by antigen loss. In this review, we are going to take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials, that are being conducted in Germany.


  • Open Access

    Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4

    by Arezoo Jamali, Jamshid Hadjati, Zahra Madjd, Hamid Reza Mirzaei, Frederic B. Thalheimer, Shiwani Agarwal, Halvard Bonig, Evelyn Ullrich, Jessica Hartmann

    Natural killer (NK) cells are a noteworthy lymphocyte subset in cancer adoptive cell therapy. NK cells initiate innate immune responses against infections and malignancies with natural cytotoxicity, which is independent of foreign antigen recognition. Based on these substantive features, genetically modifying NK cells is among the prime goals in immunotherapy but is currently difficult to achieve. Recently, we reported a fully human CAR19 construct (huCAR19) with remarkable function in gene-modified T-cells. Here, we show efficient and stable gene delivery of huCAR19 to primary human NK cells using lentiviral vectors with transduction efficiencies comparable to those achieved with NK cell lines. These huCAR19 NK cells display specific and potent cytotoxic activity against target cells. To improve homing of NK cells to the bone marrow, we augmented huCAR19 NK cells with the human CXCR4 gene, resulting in transgenically augmented CAR NK cells (TRACKs). Compared to conventional CAR NK cells, TRACKs exhibit enhanced migration capacity in response to recombinant SDF-1 or bone marrow stromal cells while retaining functional and cytolytic activity against target cells. Based on these promising findings, TRACKs may become a novel candidate for immunotherapeutic strategies in clinical applications.